EXAS
Exact Sciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Beats Expectation
Price Hits 52-week Low
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About EXAS
Exact Sciences Corporation
A leading provider of cancer screening and diagnostic tests
Biological Technology
02/10/1995
01/30/2001
NASDAQ Stock Exchange
6,900
12-31
Common stock
5505 Endeavor Lane, Madison, WI 53719
--
Exact Sciences Corporation is a molecular diagnostic company focused on the early detection and prevention of colorectal cancer. The company was merged in Delaware on February 10, 1995, and has independent intellectual property rights for non-invasive molecular detection technology, which can detect precancerous lesions of colorectal cancer and colorectal cancer. The company's goal is to become a market leader in patient-friendly diagnostic screening products, producing products for colorectal cancer precancerous lesions and early detection of colorectal cancer. To achieve this goal, the company's strategic route includes the following points: research and development of products, through the clinical approval process of the US Food and Drug Administration (FDA); commercialization of FDA-approved products, detection of colorectal cancer precancerous lesions and colorectal cancer; and substantial product compensation from product payers.
Earnings Call
Q1/2025
Estimate EPS-0.09
Actual EPS-0.54
Estimate Revenue688.63M
Actual Revenue707.00M
Exact Sciences' Q1 2025: Key Contradictions in Sales Strategy, Pricing Impact, and Revenue Forecasts
May 02,2025 07:30
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.05
Actual EPS-0.01
Estimate Revenue774.68M
Actual Revenue811.10M
Exact Sciences Q2 2025: Key Contradictions Unveiled on Blood Tests, Sales Strategies, and Market Dynamics
Aug 11,2025 04:33
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
EXAS has released its 2025 Q3 earnings. EPS was reported at 0.24, versus the expected 0.16, beating expectations. The chart below visualizes how EXAS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
EXAS has released its 2025 Q3 earnings report, with revenue of 850.74M, reflecting a YoY change of 20.05%, and net profit of -19.59M, showing a YoY change of 48.76%. The Sankey diagram below clearly presents EXAS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
